Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure

Description

This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure. The study will track patients for two years to see if those using the Cordella system have fewer deaths and hospitalizations related to heart failure.

Conditions

Heart Failure NYHA Class III, Heart Failure

Talk to us

Study Overview

On this page

Study Details

Study overview

This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure. The study will track patients for two years to see if those using the Cordella system have fewer deaths and hospitalizations related to heart failure.

The Real-World Effectiveness of The Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Failure: A Comparative Analysis to Standard of Care Pharmacologic Therapy

Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure

Condition
Heart Failure NYHA Class III
Intervention / Treatment

-

Contacts and Locations

Naperville

Endotronix, Naperville, Illinois, United States, 60563

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * No implanted pulmonary artery sensor or monitoring at any time (Standard of Care Control Cohort only)
  • * Record of temporary mechanical circulatory support during baseline period
  • * Diagnosis of cardiogenic shock during baseline period
  • * Receiving palliative care/hospice during baseline period
  • * Record of end-stage renal disease during baseline period
  • * Unable to take dual antiplatelet therapy or anticoagulants for one month post implant (Cordella Cohort only)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Endotronix, Inc.,

Joanna Van Houten, PhD, PRINCIPAL_INVESTIGATOR, Endotronix, Inc.

Study Record Dates

2030-12-31